Tata Elxsi shares gain over 5% on this development; check details

Shares of Tata Elxsi rose over 5% on Wednesday after the company announced the opening of the ‘Bayer Development Centre in Radiology’ at its Pune facility. The new unit has been set up in partnership with Bayer to develop advanced radiology devices and technologies for earlier and more accurate diagnosis of critical illnesses.

The centre will initially focus on Molecular Imaging and will handle engineering for complex radiology devices. By combining design, development and validation, it is expected to reduce costs, speed up product timelines and ensure compliance with global regulatory standards.

The collaboration draws on Tata Elxsi’s healthcare engineering expertise along with the wider Tata and India ecosystems. With access to labs, regulatory networks and specialised talent, the facility is positioned as a scalable base for innovation and will support Bayer in delivering radiology solutions across markets, including the US and EU.

Commenting on the development, Dr. Konstanze Diefenbach, Head of Research & Development, Radiology, Bayer said, “This new centre gives us direct access to specialised engineering capabilities through Tata Elxsi, enabling us to accelerate our pipeline of advanced radiology devices while maintaining the quality and reliability that healthcare providers expect from Bayer.”

Shares of Tata Elxsi settled 5.45% higher at ₹5,856 apiece on the NSE. The stock rose 5.51% to touch an intraday high of ₹5,860. The company’s market capitalisation stands at ₹36,406.89 crore.

The stock touched its 52-week high of ₹8,142.15 on September 27, 2024 and touched its 52 week low of ₹4,700 on April 7, 2025.

Over the past five days, Tata Elxsi shares surged nearly 7.83%. The stock has gained 2.96% over the last one month and climbed approximately 6.11% over the past six months.

Sreevatsa Sahasranaman, Sr. Vice President & Head – Healthcare & Life Sciences, Tata Elxsi, said, “This centre is more than an engineering hub—it is where Bayer’s radiology vision meets Tata Elxsi’s design, AI/ML, and regulatory expertise. Our teams will work together to translate ideas into devices that address real-world diagnostic challenges, with the assurance of safety, compliance, and global scalability.”

Tata Elxsi had reported a net profit of ₹144.4 crore for the quarter ended June 30, 2025 (Q1 FY26), down 21.6% from ₹184.1 crore logged in the corresponding quarter of the previous fiscal year. On a sequential basis, the numbers slipped 16.3% as the company reported a net profit of ₹172.42 crore in the March 2025 quarter (Q4 FY25).

Its revenue from operations came in at ₹892.09 crore, down 3.7% from ₹926.45 crore logged in the year-ago period. In the March 2025 quarter, the company reported revenue of ₹908.34 crore. This translates to a decline of 1.78% on a QoQ basis.

Other Income came in at ₹38.5 crore, up 19.9% YoY but down 10.7% QoQ. Total Income slipped 2.2% QoQ to ₹930.6 crore. On a YoY basis, the figure declined 2.9%.

EBITDA, or earnings before interest, taxes, depreciation, and amortisation, also known as operating profit, came in at ₹186.7 crore, down 10.1% QoQ and 26% YoY. EBIT slipped 11.2% QoQ to ₹162.4 crore. On a YoY basis, EBIT fell 27.9%.

EBITDA margin slipped to 20.9% in Q1 FY26 as against 22.9% in the previous quarter, and 27.2% in the June quarter of the fiscal year 2025.